恒瑞医药：HRS-4357注射液联合HRS-5041片获临床试验批准

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-4357 injection and HRS-5041 tablets, aimed at treating PSMA-positive prostate cancer [1] Group 1: Clinical Trial Approval - The approval includes an open, multi-center, Phase Ib/II clinical study to evaluate the safety, tolerability, and preliminary efficacy of HRS-4357 in combination with HRS-5041 for adult patients with PSMA-positive prostate cancer [1] - HRS-4357 is an innovative Class 1 radioactive therapeutic drug independently developed by the company [1] - HRS-5041 is a new, highly efficient, selective ARPROTAC small molecule developed by the company, intended for prostate cancer treatment [1] Group 2: Financial Investment - The cumulative R&D investment for the HRS-4357 injection project is approximately 67.55 million yuan [1] - The cumulative R&D investment for the HRS-5041 tablet project is approximately 92.66 million yuan [1] Group 3: Market Context - There are currently no approved products of the same kind available in both domestic and international markets [1]